Preparation of CD123 mono-antibody modified tanshinone ⅡA loaded immunoliposome and its in vitro evaluation.
10.19540/j.cnki.cjcmm.20170428.002
- Author:
Yin WANG
1
;
Fu-Rong LIU
1
;
Hong-Lin XIANG
1
;
Hong QING
1
;
Chen CHEN
1
;
Sheng-Jun MAO
1
;
Hui LI
2
Author Information
1. Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
2. Departmnt of Hematology, Sichuan Provincial People Hospital ＆ Sichuan Academy of Medical Sciences, Chengdu 610072, China.
- Publication Type:Journal Article
- Keywords:
CD123;
NB4;
tanshinoneⅡA;
immunoliposome
- From:
China Journal of Chinese Materia Medica
2017;42(11):2085-2091
- CountryChina
- Language:Chinese
-
Abstract:
In the study, we developed a novel formulation, CD123 mono-antibody (mAb) modified tanshinone ⅡA loaded immunoliposome (CD123-TanⅡA-ILP) to achieve the targeted drug delivery for leukemia cells. Orthogonal test was used to optimize liposome preparation, and the TanⅡA-loaded PEGylated liposomes (TanⅡA-LP) of S100PC-Chol-(mPEG2000-DSPE)-TanⅡA at 19∶5∶1∶1 molar ratio were prepared by the thin film hydration-probe ultrasonic method. A post-insertion method was applied to prepare CD123-TanⅡA-ILP via thiolated mAb conjugated to the terminal of maleimide-PEG2000-DSPE. The cellular uptake assay was measured by flow cytometry, and the inhibitory effect of CD123-TanⅡA-ILP on NB4 cells proliferation was tested by using MTT assay. The results of cellular uptake assay showed that CD123-ILP could significantly increase the drug uptake of NB4 cells as compared with free drugs and LP. The IC₅₀ values at 48 h incubation were 20.87, 11.71, 7.17 μmol•L⁻¹ respectively for TanⅡA，TanⅡA-LP and CD123-TanⅡA-ILP. CD123-ILP demonstrated a potential and promising targeted drug delivery strategy for acute myelogenous leukemia (AML) treatment.
